Addressing Climate Change

There are more than 5 trillion pieces of plastic floating in our oceans. The U.S. transportation sector leads all other sectors in greenhouse gas emissions. Diseases that thrive in hot weather are killing important staple crops. Our reliance on products derived from fossil fuels is harming our planet.

Climate change is real but through biotechnology, we can meet these challenges head-on by making the same reliable plastics, foods, and fuels with less environmental impact.

Press Releases
September 22, 2022
Biotechnology Industry Organization (BIO) President and CEO, Dr. Michelle McMurry-Heath, released the following statement following the announcement that Congress reached an agreement on the Prescription Drug User Fee Act (PDUFA): “For 30 years, PDUFA has been absolutely critical to…
September 13, 2022
Dr. Michelle McMurry-Heath, president & CEO of the Biotechnology Innovation Organization, released the following statement in response to the Biden Administration’s “Advancing Biotechnology and Biomanufacturing” Executive Order: “BIO welcomes the Biden Administration’s directives to…
September 8, 2022
As the Biden Administration begins implementation of the Inflation Reduction Act, the Biotechnology Innovation Organization today called on the administration to take additional steps to foster the development and deployment of pioneering technologies that are critical to meeting the nation’s…
Good Day BIO Newsletter
Subscribe to GoodDay BIO

Receive the best resource for the biotech industry with Good Day BIO, the only daily newsletter at the intersection of biotech, politics and policy. 

Letters, Comments & Testimony
September 21, 2022
On behalf of the broad and diverse stakeholders in American Agriculture we represent, we urge you to work with your colleagues to expeditiously confirm Doug  McKalip as Chief Agricultural Negotiator at the Office of the U.S. Trade Representative (USTR).
August 31, 2022
Today, BIO submitted comments in response to the FDA’s recent draft guidance on the development, maintenance, and implementation of Risk Management Plans (RMPs). While the comment letter expressed broad support for the systematic approach for establishing risk management plans (RMPs) laid out in…
September 9, 2022
Today, BIO submitted comments to the World Health Organization (WHO) regarding its revised, draft white paper on the regulation of Cell and Gene Therapy Products (CGTPs). As stated previously, BIO emphasized that this paper represents a major milestone and will be the first global regulatory…